4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Dengue Fever Clinical Trials to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Dengue Fever by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 34 ongoing clinical trials involving Dengue Fever
Of the 34 trials,10 trials are in Phase I
Furthermore, 7 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Dengue Fever by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Dengue Fever, an infectious disease. The largest number of ongoing clinical trials of Dengue Fever are in the Asia-Pacific region. North America and South and Central America are among some of the other prominent regions involved in Dengue Fever-related drug trials.

Dengue Fever related clinical trials sponsors Sanofi Pasteur SA, Dr. Mehta's Hospital Pvt Ltd, University of the Philippines System, Johnson & Johnson, and Takeda Pharmaceutical Co Ltd are a few notable clinical trials sponsors involving Dengue Fever. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Dengue Fever

Dengue vaccine (ChimeriVax Tetravalent Dengue Vaccine/Dengvaxia) is the sole key marketed drug involving Dengue Fever.

Dengue vaccine (ChimeriVax Tetravalent Dengue Vaccine/Dengvaxia) is a live, attenuated vaccine that acts as an immunizing agent. Chimeric tetravalent dengue vaccine consists of live attenuated yellow fever virus 17D strain with structural genes replaced with the corresponding dengue structural genes. The therapeutic candidate is capable of inducing a humoral immune response and cellular immune response leading to the production of B and T-lymphocytes It is formulated as a powder for suspension for the subcutaneous route of administration. It is indicated for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas. CYD (ChimeriVax-DEN) is developed by using ChimeriVax technology. ChimeriVax is a family of live, genetically engineered viruses. Dengue vaccine was first approved in 2015 and is marketed globally including the US, the UK, France, and Germany by Sanofi Pasteur Inc.

Explore the latest trends and actionable insights on the Dengue Fever Clinical Trials to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Dengue Fever Clinical Trials to inform business strategy and pinpoint opportunities and risks. Visit Report Store